IncellDx to Study Maraviroc, a CCR5 antagonist, in a COVID-19 Phase 2 Clinical Trial
SAN CARLOS, Calif., Oct. 20, 2020 /PRNewswire/ -- IncellDx will collaborate on the SARS-CoV2 Clinical Trial NCT04435522 involving Pfizer's FDA-approved CCR5 antagonist Maraviroc. The trial "Open-Label Study of Maraviroc in Hospitalized Individuals Diagnosed With SARS-CoV-2" seeks to establish whether a one week treatment with Maraviroc, used at its approved dosage for HIV, is safe and tolerable in patients with SARS-CoV-2.
Maraviroc, an oral medication, will be administered for seven days. Blood will be collected at Day 0, 3, 7 and 14. IncellDx is performing a Maraviroc-specific CCR5 Receptor Occupancy assay, their IncellKINE RUO Cytokine Storm quantification panel, immune profiling with T-cell exhaustion and macrophage polarization as well as SARS-CoV-2 plasma viral load (pVL) .
Bruce Patterson MD, CEO of IncellDx commented that "Since the beginning of the COVID-19 pandemic, IncellDx has led the way in defining the role of CCR5 antagonism in diagnosis and treatment of COVID-19. We are excited to collaborate in the study of Maraviroc's potential as a therapeutic for COVID-19. In our studies, we have shown that CCR5 antagonism can restore immune homeostasis, quiet the cytokine storm, and reduce plasma viral load of SARS-CoV-2 RNA."
About IncellDx
IncellDx, Inc., located in San Carlos, California, is a single-cell, molecular diagnostics company dedicated to revolutionizing healthcare, one cell at a time. By combining molecular diagnostics with high throughput cellular analysis, the company's focus is on critical life threatening diseases in the areas of COVID-19, infectious disease and oncology/immuno-oncology, i.e. cervical, head and neck, lung, bladder, breast and prostate cancers.
Contact:
Chris Meda, Chief Business Officer,
IncellDx, Inc.
chrism@incellDx.com
650-777-7630
View original content:http://www.prnewswire.com/news-releases/incelldx-to-study-maraviroc-a-ccr5-antagonist-in-a-covid-19-phase-2-clinical-trial-301155514.html
SOURCE IncellDx, Inc.
